A global, phase III clinical trial evaluating the safety and efficacy of TAVT-45 (abiraterone acetate) granules for oral suspension, an investigational enhanced formulation of abiraterone acetate for the treatment of metastatic prostate cancer, produced positive topline results.
To access this subscriber-only content please log in or renew your subscription.
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe